{"id":58290,"date":"2026-02-27T19:09:01","date_gmt":"2026-02-27T11:09:01","guid":{"rendered":"https:\/\/flcube.com\/?p=58290"},"modified":"2026-02-27T19:09:02","modified_gmt":"2026-02-27T11:09:02","slug":"wuxi-xdc-licenses-wuxitecan-2-technology-to-earendil-labs-885m-deal-powers-ai-driven-adc-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58290","title":{"rendered":"WuXi XDC Licenses WuXiTecan-2 Technology to Earendil Labs \u2013 $885M Deal Powers AI\u2011Driven ADC Development"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>WuXi XDC (<a href=\"https:\/\/www.google.com\/finance\/quote\/2268:HKG\">HKG:\u202f2268<\/a>)<\/strong>, a <strong>leading global end\u2011to\u2011end CRDMO<\/strong>, announced a <strong>strategic collaboration<\/strong> with <strong>Earendil Labs<\/strong>, the overseas subsidiary of <strong>Helixon<\/strong>, to license its proprietary <strong>WuXiTecan\u20112 payload\u2011linker technology<\/strong>. The deal enables Earendil to combine WuXi XDC&#8217;s <strong>ADC technology<\/strong> with its <strong>AI\u2011discovered bispecific antibodies<\/strong> to advance next\u2011generation ADC candidates across multiple targets.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-overview\">Transaction Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensor<\/strong><\/td><td>WuXi XDC (HKG:\u202f2268) \u2013 global ADC CRDMO<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>Earendil Labs (overseas subsidiary of Helixon)<\/td><\/tr><tr><td><strong>Licensed Technology<\/strong><\/td><td>WuXiTecan\u20112 Payload\u2011Linker Technology<\/td><\/tr><tr><td><strong>Application<\/strong><\/td><td>ADC development against multiple specific targets<\/td><\/tr><tr><td><strong>Integration<\/strong><\/td><td>Earendil&#8217;s AI\u2011discovered bispecific antibodies + WuXiTecan\u20112<\/td><\/tr><tr><td><strong>Total Deal Value<\/strong><\/td><td>Up to <strong>~\u202fUSD\u202f885\u202fmillion<\/strong><\/td><\/tr><tr><td><strong>Payment Structure<\/strong><\/td><td>Upfront + R&amp;D milestones + regulatory milestones + sales milestones<\/td><\/tr><tr><td><strong>Royalties<\/strong><\/td><td>Tiered royalties on net sales post\u2011commercialization<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-synergy\">Technology Synergy<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Partner<\/th><th>Platform\/Technology<\/th><th>Contribution<\/th><\/tr><\/thead><tbody><tr><td><strong>WuXi XDC<\/strong><\/td><td>WuXiTecan\u20112 Payload\u2011Linker<\/td><td>Proprietary ADC linker\u2011payload technology; manufacturing scale\u2011up<\/td><\/tr><tr><td><strong>Earendil Labs \/ Helixon<\/strong><\/td><td>AI\u2011driven biologics discovery<\/td><td>Bispecific antibody candidates against autoimmune diseases, cancer<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>ADC Technology Monetization:<\/strong> WuXi XDC leverages its <strong>WuXiTecan\u20112 platform<\/strong>\u2014beyond manufacturing services\u2014to capture <strong>downstream value<\/strong> through licensing and milestone participation in partner programs.<\/li>\n\n\n\n<li><strong>AI\u2011ADC Convergence:<\/strong> Earendil&#8217;s <strong>AI\u2011discovered bispecific antibodies<\/strong> combined with WuXi XDC&#8217;s <strong>validated payload\u2011linker technology<\/strong> accelerates ADC candidate optimization, potentially improving tumor selectivity and therapeutic index.<\/li>\n\n\n\n<li><strong>Bispecific ADC Innovation:<\/strong> The collaboration targets <strong>bispecific ADCs<\/strong>\u2014an emerging class with potential to address tumor heterogeneity and resistance vs. traditional monoclonal ADCs.<\/li>\n\n\n\n<li><strong>Helixon Global Expansion:<\/strong> Earendil Labs&#8217; partnership with a <strong>tier\u2011one ADC CRDMO<\/strong> validates its AI platform and provides technology access for <strong>international clinical development<\/strong>.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>ADC Market Growth<\/strong><\/td><td>Projected &gt;\u202f$30\u202fbillion by 2030; bispecific ADCs represent next\u2011wave innovation<\/td><\/tr><tr><td><strong>CRDMO Platform Licensing<\/strong><\/td><td>WuXi XDC joins Lonza, Catalent in technology licensing strategies beyond pure manufacturing<\/td><\/tr><tr><td><strong>AI\u2011Drug Discovery Validation<\/strong><\/td><td>$885M deal value signals investor and partner confidence in AI\u2011driven biologics discovery<\/td><\/tr><tr><td><strong>China Biotech Globalization<\/strong><\/td><td>Helixon\/Earendil partnership with WuXi XDC enables worldwide ADC development from China\u2011originated AI platform<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding ADC candidate advancement, milestone achievement, and commercial potential. Actual results may differ due to risks including bispecific ADC technical challenges, competitive program developments, and manufacturing technology transfer complexity.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>WuXi XDC (HKG:\u202f2268), a leading global end\u2011to\u2011end CRDMO, announced a strategic collaboration with Earendil Labs,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":58291,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[99,19,4017,3904,1183,364],"class_list":["post-58290","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-ai","tag-cro-cmo-cdmo","tag-earendil-labs","tag-helixon","tag-hkg-2268","tag-wuxi-xdc"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>WuXi XDC Licenses WuXiTecan-2 Technology to Earendil Labs \u2013 $885M Deal Powers AI\u2011Driven ADC Development - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"WuXi XDC (HKG:\u202f2268), a leading global end\u2011to\u2011end CRDMO, announced a strategic collaboration with Earendil Labs, the overseas subsidiary of Helixon, to license its proprietary WuXiTecan\u20112 payload\u2011linker technology. The deal enables Earendil to combine WuXi XDC&#039;s ADC technology with its AI\u2011discovered bispecific antibodies to advance next\u2011generation ADC candidates across multiple targets.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=58290\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"WuXi XDC Licenses WuXiTecan-2 Technology to Earendil Labs \u2013 $885M Deal Powers AI\u2011Driven ADC Development\" \/>\n<meta property=\"og:description\" content=\"WuXi XDC (HKG:\u202f2268), a leading global end\u2011to\u2011end CRDMO, announced a strategic collaboration with Earendil Labs, the overseas subsidiary of Helixon, to license its proprietary WuXiTecan\u20112 payload\u2011linker technology. The deal enables Earendil to combine WuXi XDC&#039;s ADC technology with its AI\u2011discovered bispecific antibodies to advance next\u2011generation ADC candidates across multiple targets.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=58290\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-27T11:09:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-27T11:09:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2702.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58290#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58290\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"WuXi XDC Licenses WuXiTecan-2 Technology to Earendil Labs \u2013 $885M Deal Powers AI\u2011Driven ADC Development\",\"datePublished\":\"2026-02-27T11:09:01+00:00\",\"dateModified\":\"2026-02-27T11:09:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58290\"},\"wordCount\":380,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58290#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/2702.webp\",\"keywords\":[\"AI\",\"CRO \\\/ CMO \\\/ CDMO\",\"Earendil Labs\",\"Helixon\",\"HKG: 2268\",\"WuXi XDC\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58290#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58290\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=58290\",\"name\":\"WuXi XDC Licenses WuXiTecan-2 Technology to Earendil Labs \u2013 $885M Deal Powers AI\u2011Driven ADC Development - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58290#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58290#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/2702.webp\",\"datePublished\":\"2026-02-27T11:09:01+00:00\",\"dateModified\":\"2026-02-27T11:09:02+00:00\",\"description\":\"WuXi XDC (HKG:\u202f2268), a leading global end\u2011to\u2011end CRDMO, announced a strategic collaboration with Earendil Labs, the overseas subsidiary of Helixon, to license its proprietary WuXiTecan\u20112 payload\u2011linker technology. The deal enables Earendil to combine WuXi XDC's ADC technology with its AI\u2011discovered bispecific antibodies to advance next\u2011generation ADC candidates across multiple targets.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58290#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58290\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58290#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/2702.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/2702.webp\",\"width\":1080,\"height\":608,\"caption\":\"WuXi XDC Licenses WuXiTecan-2 Technology to Earendil Labs \u2013 $885M Deal Powers AI\u2011Driven ADC Development\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58290#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"WuXi XDC Licenses WuXiTecan-2 Technology to Earendil Labs \u2013 $885M Deal Powers AI\u2011Driven ADC Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"WuXi XDC Licenses WuXiTecan-2 Technology to Earendil Labs \u2013 $885M Deal Powers AI\u2011Driven ADC Development - Insight, China&#039;s Pharmaceutical Industry","description":"WuXi XDC (HKG:\u202f2268), a leading global end\u2011to\u2011end CRDMO, announced a strategic collaboration with Earendil Labs, the overseas subsidiary of Helixon, to license its proprietary WuXiTecan\u20112 payload\u2011linker technology. The deal enables Earendil to combine WuXi XDC's ADC technology with its AI\u2011discovered bispecific antibodies to advance next\u2011generation ADC candidates across multiple targets.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=58290","og_locale":"en_US","og_type":"article","og_title":"WuXi XDC Licenses WuXiTecan-2 Technology to Earendil Labs \u2013 $885M Deal Powers AI\u2011Driven ADC Development","og_description":"WuXi XDC (HKG:\u202f2268), a leading global end\u2011to\u2011end CRDMO, announced a strategic collaboration with Earendil Labs, the overseas subsidiary of Helixon, to license its proprietary WuXiTecan\u20112 payload\u2011linker technology. The deal enables Earendil to combine WuXi XDC's ADC technology with its AI\u2011discovered bispecific antibodies to advance next\u2011generation ADC candidates across multiple targets.","og_url":"https:\/\/flcube.com\/?p=58290","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-27T11:09:01+00:00","article_modified_time":"2026-02-27T11:09:02+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2702.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=58290#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=58290"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"WuXi XDC Licenses WuXiTecan-2 Technology to Earendil Labs \u2013 $885M Deal Powers AI\u2011Driven ADC Development","datePublished":"2026-02-27T11:09:01+00:00","dateModified":"2026-02-27T11:09:02+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=58290"},"wordCount":380,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=58290#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2702.webp","keywords":["AI","CRO \/ CMO \/ CDMO","Earendil Labs","Helixon","HKG: 2268","WuXi XDC"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=58290#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=58290","url":"https:\/\/flcube.com\/?p=58290","name":"WuXi XDC Licenses WuXiTecan-2 Technology to Earendil Labs \u2013 $885M Deal Powers AI\u2011Driven ADC Development - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=58290#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=58290#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2702.webp","datePublished":"2026-02-27T11:09:01+00:00","dateModified":"2026-02-27T11:09:02+00:00","description":"WuXi XDC (HKG:\u202f2268), a leading global end\u2011to\u2011end CRDMO, announced a strategic collaboration with Earendil Labs, the overseas subsidiary of Helixon, to license its proprietary WuXiTecan\u20112 payload\u2011linker technology. The deal enables Earendil to combine WuXi XDC's ADC technology with its AI\u2011discovered bispecific antibodies to advance next\u2011generation ADC candidates across multiple targets.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=58290#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=58290"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=58290#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2702.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2702.webp","width":1080,"height":608,"caption":"WuXi XDC Licenses WuXiTecan-2 Technology to Earendil Labs \u2013 $885M Deal Powers AI\u2011Driven ADC Development"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=58290#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"WuXi XDC Licenses WuXiTecan-2 Technology to Earendil Labs \u2013 $885M Deal Powers AI\u2011Driven ADC Development"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2702.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58290","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=58290"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58290\/revisions"}],"predecessor-version":[{"id":58292,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58290\/revisions\/58292"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/58291"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=58290"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=58290"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=58290"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}